Multiply Labs raises $75 million in a Series B led by medical researcher Patrick Soon-Shiong, with AstraZeneca and robotics maker Teradyne among more than half a dozen other backers. Its robotics clusters use robotic arms, specialized enclosures and customer-trained AI to automate pharmaceutical production steps while imitating existing manual workflows. The company focuses on cell and gene therapies, says its technology can increase throughput 100-fold and lower cost per dose by 74%, and plans to expand therapy support and production capacity.
Multiply Labs and AstraZeneca are collaborating on GMP-ready robotics to automate cell therapy manufacturing. Multiply Labs executive Parietti comments on the partnership.
Multiply Labs unveiled a peer-reviewed study with UCSF reporting that robotic cell expansion matched the performance of a manual process while reducing costs. The supplied article text provides no further details about the study’s methods or results.
Multiply Labs uses robotic clusters to automate production of customized drug capsules for clinical trials. The company plans to bring that production capability to cell therapies.
